These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 19232474)

  • 1. Novel agents for renal cell carcinoma require novel selection paradigms to optimise first-line therapy.
    Schmidinger M; Zielinski CC
    Cancer Treat Rev; 2009 May; 35(3):289-96. PubMed ID: 19232474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tolerability of first-line therapy for metastatic renal cell carcinoma.
    Porta C; Szczylik C
    Cancer Treat Rev; 2009 May; 35(3):297-307. PubMed ID: 19249157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation.
    Thompson Coon J; Hoyle M; Green C; Liu Z; Welch K; Moxham T; Stein K
    Health Technol Assess; 2010 Jan; 14(2):1-184, iii-iv. PubMed ID: 20028613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib.
    Mickisch G; Gore M; Escudier B; Procopio G; Walzer S; Nuijten M
    Br J Cancer; 2010 Jan; 102(1):80-6. PubMed ID: 19920817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First-line therapy for treatment-naive patients with advanced/metastatic renal cell carcinoma: a systematic review of published randomized controlled trials.
    Takyar S; Diaz J; Sehgal M; Sapunar F; Pandha H
    Anticancer Drugs; 2016 Jun; 27(5):383-97. PubMed ID: 26886011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal management of metastatic renal cell carcinoma: an algorithm for treatment.
    Bellmunt J; Flodgren P; Roigas J; Oudard S
    BJU Int; 2009 Jul; 104(1):10-8. PubMed ID: 19388982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness.
    Thompson Coon JS; Liu Z; Hoyle M; Rogers G; Green C; Moxham T; Welch K; Stein K
    Br J Cancer; 2009 Jul; 101(2):238-43. PubMed ID: 19568242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on systemic therapies of metastatic renal cell carcinoma.
    Herrmann E; Bierer S; Wülfing C
    World J Urol; 2010 Jun; 28(3):303-9. PubMed ID: 20180125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].
    Miller K; Bergmann L; Albers P; Gschwend J; Jäger E; Keilholz U
    Aktuelle Urol; 2010 May; 41(3):193-6. PubMed ID: 20486036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies.
    Hutson TE; Figlin RA; Kuhn JG; Motzer RJ
    Oncologist; 2008 Oct; 13(10):1084-96. PubMed ID: 18838439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bevacizumab plus interferon-α versus sunitinib for first-line treatment of renal cell carcinoma in Italy: a cost-minimization analysis.
    Ravasio R; Ortega C; Sabbatini R; Porta C
    Clin Drug Investig; 2011; 31(7):507-17. PubMed ID: 21627339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advances in the systemic treatment of metastatic papillary renal cancer.
    Chowdhury S; Choueiri TK
    Expert Rev Anticancer Ther; 2009 Mar; 9(3):373-9. PubMed ID: 19275514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [First-line therapy of metastatic renal cell carcinoma--update 2009].
    Miller K
    Onkologie; 2010; 33 Suppl 1():5-9. PubMed ID: 20164669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Evaluation of the management of metastatic renal cell carcinoma in the era of targeted therapies. retrospective clinical study over six years].
    Latteux G; Lebdai S; Hoarau N; Abadie-Lacourtoisie S; Delva R; Chautard D; Azzouzi AR; Bigot P
    Prog Urol; 2013 Mar; 23(3):184-94. PubMed ID: 23446283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].
    Miller K; Bergmann L; Jäger E; Jakse G; Wirth M; Keilholz U;
    Aktuelle Urol; 2009 Jan; 40(1):27-30. PubMed ID: 19177318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy for metastatic renal cell carcinoma.
    Unverzagt S; Moldenhauer I; Nothacker M; Roßmeißl D; Hadjinicolaou AV; Peinemann F; Greco F; Seliger B
    Cochrane Database Syst Rev; 2017 May; 5(5):CD011673. PubMed ID: 28504837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent advances in the treatment of renal cell carcinoma and the role of targeted therapies.
    Chowdhury S; Larkin JM; Gore ME
    Eur J Cancer; 2008 Oct; 44(15):2152-61. PubMed ID: 18829302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Good response to second-line bevacizumab and interferon-alpha in a sunitinib-refractory patient with metastatic renal cell carcinoma.
    Pastorelli D; Zustovich F; Faggioni G; Zovato S; Donach M; Nicoletto O; Farina M; Furini L; Ceravolo R; Carli P; Lombardi G
    Anticancer Drugs; 2010 Feb; 21(2):210-3. PubMed ID: 19952729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploring the role of novel agents in the treatment of renal cell carcinoma.
    Maluf FC; Fernandes Gdos S; Kann AG; Aguilar-Ponce JL; de la Garza J; Buzaid AC
    Cancer Treat Rev; 2008 Dec; 34(8):750-60. PubMed ID: 18801619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial.
    Négrier S; Gravis G; Pérol D; Chevreau C; Delva R; Bay JO; Blanc E; Ferlay C; Geoffrois L; Rolland F; Legouffe E; Sevin E; Laguerre B; Escudier B
    Lancet Oncol; 2011 Jul; 12(7):673-80. PubMed ID: 21664867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.